派傑投資維持Agios Pharmaceuticals(AGIO.US)買入評級,維持目標價56美元
Scotiabank宣佈agios pharmaceuticals股票的目標價格爲51.00美元/股。
Leerink Partners維持Agios Pharmaceuticals(AGIO.US)持有評級
瑞傑金融上調Agios Pharmaceuticals(AGIO.US)至買入評級,目標價51美元
agios pharmaceuticals分析師評級
agios pharmaceuticals被雷蒙德詹姆斯評爲表現優異
Leerink Partners維持Agios Pharmaceuticals(AGIO.US)持有評級,維持目標價56美元
Leerink Partners下調Agios Pharmaceuticals(AGIO.US)至持有評級,下調目標價至56美元
Agios Pharmaceuticals在Leerink的評級由Outperform下調至Market Perform
美銀證券維持Agios Pharmaceuticals(AGIO.US)買入評級,上調目標價至57美元
派傑投資維持Agios Pharmaceuticals(AGIO.US)買入評級,維持目標價56美元
agios pharmaceuticals分析師評級
加皇資本市場維持Agios Pharmaceuticals(AGIO.US)買入評級,維持目標價55美元
派傑投資維持Agios Pharmaceuticals(AGIO.US)買入評級,維持目標價56美元
agios pharmaceuticals分析師評級
TD Cowen維持Agios Pharmaceuticals(AGIO.US)買入評級
加皇資本市場維持Agios Pharmaceuticals(AGIO.US)買入評級,上調目標價至55美元
TD Cowen維持Agios Pharmaceuticals(AGIO.US)買入評級
派傑投資維持Agios Pharmaceuticals(AGIO.US)買入評級,維持目標價55美元
agios pharmaceuticals分析師評級